Ph-negative myeloproliferative neoplasms (MPNs) are hematological cancers that can be
subdivided into entities with distinct clinical features. Somatic mutations in JAK2, CALR, and …

Abstract The Philadelphia chromosome–negative (Ph−) myeloproliferative neoplasms
(MPNs) are a heterogenous group of hematopoietic stem cell diseases characterized by …

Myeloproliferative neoplasms (MPNs) are a group of related clonal hematologic disorders
characterized by excess accumulation of one or more myeloid cell lineages and a tendency …

Despite distinct clinical entities, the myeloproliferative neoplasms (MPN) share
morphological similarities, propensity to thrombotic events and leukemic evolution, and a …

The myeloproliferative neoplasms (MPNs) are acquired hematological stem cell neoplasms
characterized by driver mutations in JAK2, CALR, or MPL. Additive mutations may appear in …

The myeloproliferative neoplasms (MPN) polycythaemia vera, essential thrombocythaemia
and primary myelofibrosis are chronic myeloid disorders associated most often with …

Activated JAK-STAT signaling is central to the pathogenesis of BCR-ABL-negative
myeloproliferative neoplasms (MPNs) and occurs as a result of MPN phenotypic driver …

The Philadelphia-negative myeloproliferative neoplasms (MPNs) are malignancies of the
hematopoietic stem cell (HSC) arising as a consequence of clonal proliferation driven by …

Genomic studies have identified somatic alterations in the majority of myeloproliferative
neoplasms (MPN) patients, including JAK2 mutations in the majority of MPN patients and …

Our understanding of the genetic basis of the Philadelphia chromosome-negative
myeloproliferative neoplasms (MPNs) has moved forward at a staggering pace over the last …